Hap Trading, LLC Altimmune, Inc. Call Options Transaction History

Hap Trading, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $378,357 - $1.52 Million	90,300 New	90,300 $0
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $696,938 - $1 Million	-80,200 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$8.43 - $16.81 $676,086 - $1.35 Million	80,200 New	80,200 $6,000
Q2 2020 Aug 10, 2020	SELL	$2.9 - $10.71 $34,800 - $128,520	-12,000 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$1.69 - $3.8 $20,280 - $45,600	12,000 New	12,000 $13,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $349M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.